Lactobacillus GG as an immune adjuvant for live-attenuated influenza vaccine in healthy adults: a randomized double-blind placebo-controlled trial
Open Access
- 2 February 2011
- journal article
- research article
- Published by Springer Science and Business Media LLC in European Journal of Clinical Nutrition
- Vol. 65 (4), 501-507
- https://doi.org/10.1038/ejcn.2010.289
Abstract
Background/Objectives: Live-attenuated influenza vaccine (LAIV) protects against influenza by mucosal activation of the immune system. Studies in animals and adults have demonstrated that probiotics improve the immune response to mucosally delivered vaccines. We hypothesized that Lactobacillus GG (LGG) would function as an immune adjuvant to increase rates of seroconversion after LAIV administration. Subjects/Methods: We conducted a randomized double-blind placebo-controlled pilot study to determine whether LGG improved rates of seroconversion after administration of LAIV. We studied 42 healthy adults during the 2007–2008 influenza season. All subjects received LAIV and then were randomized to LGG or placebo, twice daily for 28 days. Hemagglutinin inhibition titers were assessed at baseline, at day 28 and at day 56 to determine the rates of seroconversion. Subjects were assessed for adverse events throughout the study period. Results: A total of 39 subjects completed the per-protocol analysis. Both LGG and LAIV were well tolerated. Protection rates against the vaccine H1N1 and B strains were suboptimal in subjects receiving LGG and placebo. For the H3N2 strain, 84% receiving LGG vs 55% receiving placebo had a protective titer 28 days after vaccination (odds of having a protective titer was 1.84 95% confidence interval 1.04–3.22, P=0.048). Conclusion: Lactobacillus GG is potential as an important adjuvant to improve influenza vaccine immunogenicity. Future studies of probiotics as immune adjuvants might need to specifically consider examining vaccine-naïve or sero-negative subjects, target mucosal immune responses or focus on groups known to have poor response to influenza vaccines.Keywords
This publication has 37 references indexed in Scilit:
- Probiotics and the immune response to vaccinesProceedings of the Nutrition Society, 2010
- Specific Recognition of Influenza A/H1N1/2009 Antibodies in Human Serum: A Simple Virus-Free ELISA MethodPLOS ONE, 2010
- Oral administration of lactobacilli from human intestinal tract protects mice against influenza virus infectionLetters in Applied Microbiology, 2010
- Intranasal administration of Lactobacillus rhamnosus GG protects mice from H1N1 influenza virus infection by regulating respiratory immune responsesLetters in Applied Microbiology, 2010
- Trial of 2009 Influenza A (H1N1) Monovalent MF59-Adjuvanted VaccineThe New England Journal of Medicine, 2009
- Comparative Efficacy of Inactivated and Live Attenuated Influenza VaccinesThe New England Journal of Medicine, 2009
- Reduced reaction frequencies with repeated inactivated or live-attenuated influenza vaccinationVaccine, 2009
- Intradermal Influenza Vaccine Administered Using a New Microinjection System Produces Superior Immunogenicity in Elderly Adults: A Randomized Controlled TrialThe Journal of Infectious Diseases, 2008
- Influence of Prior Influenza Vaccination on Antibody and B-Cell ResponsesPLOS ONE, 2008
- Prevention of Antigenically Drifted Influenza by Inactivated and Live Attenuated VaccinesThe New England Journal of Medicine, 2006